Carlisle Companies Incorporated CSL reported impressive third-quarter 2022 results, wherein both the bottom and the top line surpassed the Zacks Consensus Estimate. Following this stellar performance, ...
CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results